EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieKlinische Studie (Phase II)Multizentrische StudieVergleichsstudieOpen Access · CC BY 4.0

Efficacy, safety, pharmacokinetics, and associated microbiome changes of ibezapolstat compared with vancomycin in adults with Clostridioides difficile infection: a phase 2b, randomised, double-blind, active-controlled, multicentre study

Taryn A Eubank, Jinhee Jo, M Jahangir Alam, Khurshida Begum, Jacob K McPherson, ThanhPhuong M Le, Thomas D Horvath, Sigmund J Haidacher, Eugene C Poggio, Rong Lin, Corinne Seng Yue, Murray P Ducharme und 6 weitere

The Lancet Microbe · 2025

DOI: 10.1016/j.lanmic.2025.101126 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift The Lancet Microbe, 2025. Verfasst von Taryn A Eubank und 17 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy Practice and Translational Research, University of Houston College of Pharmacy, Houston, TX, USA. Hauptthemen laut MEDLINE: Vancomycin, Clostridium Infections, Anti-Bacterial Agents, Clostridioides difficile. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIAID NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Clostridioides difficile infection is a common health-care-associated and community-acquired disease with few antibiotic treatment options. We aimed to assess the safety, efficacy, pharmacokinetics, and associated microbiome changes of ibezapolstat, an antibiotic that inhibits the PolC-type DNA polymerase III α subunit C, versus vancomycin for the treatment of C difficile infection in adults. METHODS: This was a phase 2b, randomised, double-blind, active-controlled study conducted at 15 centres, primarily outpatient clinics and hospitals, in the USA. Adults aged 18-90 years, with signs and symptoms of C difficile infection and a positive toxin stool test were recruited. Participants were randomly assigned (1:1) with block assignment by study site using an interactive web response system to receive oral ibezapolstat (450 mg twice daily) or oral vancomycin (125 mg every 6 h) for 10 days. Masking was achieved by over-encapsulation of both study drugs (ibezapolstat and vancomycin) and placebo into identically sized capsules. Participants were excluded if they had received more than 24 h of treatment with oral vancomycin, fidaxomicin, or metronidazole for the current episode of C difficile infection before the first dose of study drug or any other antibacterial therapy within 48 h, had had more than three episodes of C difficile infection in the previous 12 months, or had had more than one previous episode in the past 3 months (excluding the current episode). The primary efficacy endpoint was initial clinical cure maintained for at least 48 h after the end of treatment. All individuals with C difficile infection who met inclusion and exclusion criteria, were randomly assigned, and were administered at least one dose of study drug were included in the efficacy analysis. The safety and tolerability of ibezapolstat was assessed in all individuals who were administered at least one dose of study drug. This study is registered with ClinicalTrials.gov, NCT04247542. FINDINGS: Between March 12, 2021, and Oct 27, 2023, 39 individuals were assessed for eligibility, 32 of whom were recruited and randomly assigned to ibezapolstat (n=18) or vancomycin (n=14). Two participants were excluded from the efficacy analysis: one participant in the ibezapolstat group withdrew consent before receiving the study drug and another was identified after random assignment as having an exclusion criterion. The primary efficacy analysis included 16 participants in the ibezapolstat group and 14 in the vancomycin group; 24 (80%) participants were female and six (20%) were male. 15 (94%) of 16 participants in the ibezapolstat group had initial clinical cure compared with 14 (100%) of 14 participants in the vancomycin group (treatment difference -6·3% [95% CI -30·7 to 19·4]; p=1·0). Ibezapolstat was well tolerated with a safety profile similar to vancomycin. No drug-related serious adverse events, drug-related treatment withdrawal, or treatment-related deaths occurred in either group. INTERPRETATION: Ibezapolstat is a Gram-positive selective spectrum antibiotic that shows potential in the treatment of initial C difficile infection and prevention of recurrence. Further clinical development is warranted. FUNDING: Acurx Pharmaceuticals.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

VancomycinClostridium InfectionsAnti-Bacterial AgentsClostridioides difficileHumansDouble-Blind MethodMiddle AgedMaleFemaleAdultAgedAged, 80 and overYoung AdultAdolescentTreatment OutcomePeptides, CyclicPurine NucleosidesLipopeptides

Substanzen

VancomycinAnti-Bacterial AgentsCB-183,315IbezapolstatPeptides, CyclicPurine NucleosidesLipopeptides

Autor:innen und Institutionen

  • Department of Pharmacy Practice and Translational Research, University of Houston College of Pharmacy, Houston, TX, USA.
  • Department of Pharmacy Practice and Translational Research, University of Houston College of Pharmacy, Houston, TX, USA; Department of Pathology and Immunology, Baylor College of Medicine, Houston, TX, USA; Texas Childr…
  • Department of Pathology and Immunology, Baylor College of Medicine, Houston, TX, USA; Texas Children's Microbiome Center, Department of Pathology, Texas Children's Hospital, Houston, TX, USA.
  • Biostatistical Consulting, Lexington, MA, USA.
  • Learn and Confirm, Montreal, QC, Canada.
  • Altasciences Company, Montreal, QC, Canada.

Förderung

  • NIAID NIH HHS

Zitieren

APA

Eubank, T. A., Jo, J., Alam, M. J., Begum, K., McPherson, J. K., Le, T. M., Horvath, T. D., Haidacher, S. J., Poggio, E. C., Lin, R., Yue, C. S., Ducharme, M. P., Koudssi, G., Mercier, J., Alder, J. D., Silverman, M. H., Garey, K. W., & Ibezapolstat Phase 2 Investigator Group (2025). Efficacy, safety, pharmacokinetics, and associated microbiome changes of ibezapolstat compared with vancomycin in adults with Clostridioides difficile infection: a phase 2b, randomised, double-blind, active-controlled, multicentre study. The Lancet Microbe. https://doi.org/10.1016/j.lanmic.2025.101126

Vancouver

Eubank TA, Jo J, Alam MJ, Begum K, McPherson JK, Le TM, et al. Efficacy, safety, pharmacokinetics, and associated microbiome changes of ibezapolstat compared with vancomycin in adults with Clostridioides difficile infection: a phase 2b, randomised, double-blind, active-controlled, multicentre study. The Lancet Microbe. 2025. doi:10.1016/j.lanmic.2025.101126

BibTeX
@article{Eubank2025,
  author = {Eubank, Taryn A and Jo, Jinhee and Alam, M Jahangir and Begum, Khurshida and McPherson, Jacob K and Le, ThanhPhuong M and Horvath, Thomas D and Haidacher, Sigmund J and Poggio, Eugene C and Lin, Rong and Yue, Corinne Seng and Ducharme, Murray P and Koudssi, Georges and Mercier, Julie and Alder, Jeffrey D and Silverman, Michael H and Garey, Kevin W and Ibezapolstat Phase 2 Investigator Group, Ibezapolstat Phase 2 Investigator Group},
  title = {Efficacy, safety, pharmacokinetics, and associated microbiome changes of ibezapolstat compared with vancomycin in adults with Clostridioides difficile infection: a phase 2b, randomised, double-blind, active-controlled, multicentre study},
  journal = {The Lancet Microbe},
  year = {2025},
  doi = {10.1016/j.lanmic.2025.101126}
}
Kostenlos starten →